"""Current in silico software is only accessible to large pharmaceutical companies willing to pay obnoxious licensing fees. Students in every country no matter their university, startup companies to Fortune 500s, and even dedicated hobbyists will all have the same opportunity to design new molecules to change the future of drug discovery," said Shkreli, co-founder of Druglike."""
FWIW, my company's software is free to academics. This article hides the fact that the majority of the economic barrier to entry is not licensing but the cost of performing the large-scale simulations necessary to do docking, md, generating conformers, or what-have-you. Drug discovery is computationally hard and if AWS or whoever is going to ultimately charge for compute then someone along the path will need to pay for that compute. Just my two cents.
-. --- - / ...- .- .-.. .. -.. / -- --- .-. ... . / -.-. --- -.. . FRIAM Applied Complexity Group listserv Fridays 9a-12p Friday St. Johns Cafe / Thursdays 9a-12p Zoom https://bit.ly/virtualfriam to (un)subscribe http://redfish.com/mailman/listinfo/friam_redfish.com FRIAM-COMIC http://friam-comic.blogspot.com/ archives: 5/2017 thru present https://redfish.com/pipermail/friam_redfish.com/ 1/2003 thru 6/2021 http://friam.383.s1.nabble.com/
